Skip to content
No results
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Strategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • PRMT5 Inhibitor (AT101)
    • Cancer Vaccine (PCV001)
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx
  • Home
  • About
    • Executive Team
    • Board of Directors
    • Strategic Collaborations
    • Careers
  • Products
    • Zabadinostat (CXD101)
    • PRMT5 Inhibitor (AT101)
    • Cancer Vaccine (PCV001)
  • Press Releases
  • Pipeline
  • Publications
  • Contact
IngenOx

Tailoring treatment and trials to prognosis

August 10, 2013

Tailoring treatment and trials to prognosis.
Nature Reviews – August 2013

 

Kerr-and-Shi-Nature-Reviews.2013.97

Share This Post

XFacebookLinkedInMessengerWhatsApp

Posts navigation

← Use of multivariate analysis to suggest a new molecular classification of colorectal cancer
Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer →

More Posts

Interim Phase 2 Results Suggest Zabadinostat Combination Improves Overall Survival in Advanced Liver Cancer

February 26, 2025

IngenOx Therapeutics Chief Medical Officer Meets Chinese Premier to Advance International Anti-Cancer Cooperation

February 10, 2025

IngenOx Therapeutics CMO Receives China Friendship Medal

October 21, 2024
IngenOx

  • Registered Address: Magdalen Centre Oxford Science Park Robert Robinson Avenue Oxford, OX4 4GA
  • Email: enquiries@ingenOx.com

Products

  • Zabadinostat (CXD101)
  • PRMT5 Inhibitor (AT101)
  • Cancer Vaccine (PCV001)
  • Pipeline

About Us

  • About
  • Executive Team
  • Board of Directors
  • Strategic Collaborations

Useful Links

  • Careers
  • Press Releases
  • Publications
  • Contact

Copyright © 2025 

  • Anti-Slavery Statement
  • Privacy Statement